Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin photodynamic therapy (PDT) for the treatment of prolonged unresolved central serous chorioretinopathy (CSCR).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shin Kong Wu Ho-Su Memorial Hospital
• Treatments: Verteporfin

Criteria

Inclusion Criteria:

• Patients with best-corrected visual acuity (BCVA) of 20/200 or better

• Presence of subretinal fluid (SRF) and/or serous pigment epithelial detachment (PED) involving the fovea on optical coherence tomography (OCT)

• Presence of active angiographic leakage in fluorescein angiography (FA) caused by CSC but not CNV or other diseases

• Abnormal dilated choroidal vasculature and other features in ICGA consistent with the diagnosis of CSC.

Exclusion Criteria:

• Patients who received previous PDT or focal thermal laser photocoagulation for the treatment of CSC.

• Patients had evidence of CNV, polypoidal choroidal vasculopathy, or other maculopathy on clinical examination, FA, or ICGA